Abstract
We conducted a prospective, controlled, randomized trial of oral trimethoprim-sulfamethoxazole treatment in patients with acute leukemia receiving consolidation chemotherapy. We followed 14 treatment patients during 33 episodes and 15 control patients during 34 episodes of granulocytopenia (less than 1000 granulocytes/mm 3). We found no significant difference in the incidence of febrile episodes (13 in treatment group versus 14 in control group), hospitilizations to treat fever or infection (10 versus 12),number of documented infections (8 versus 10), number of septicemias (one versus two), or mean duration of hospital stay to treat fever or infection (8.9 versus 9.2 days) in the two groups. There was little colonization with organisms resistant to trimethoprim-sulfamethoxazole, including Candida, in either group. Prophylactic trimethoprim-sulfamethoxazole did not significantly reduce the incidence of fever, hospitalization, or infection in granulocytopenic patients during consolidation chemotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 436-438 |
| Number of pages | 3 |
| Journal | Annals of Internal Medicine |
| Volume | 95 |
| Issue number | 4 |
| State | Published - 1981 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia : A controlled trial. / Weiser, Barbara; Lange, M.; Fialk, M. A.; Singer, C.; Szatrowski, T. H.; Armstrong, D.
In: Annals of Internal Medicine, Vol. 95, No. 4, 1981, p. 436-438.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia
T2 - A controlled trial
AU - Weiser, Barbara
AU - Lange, M.
AU - Fialk, M. A.
AU - Singer, C.
AU - Szatrowski, T. H.
AU - Armstrong, D.
PY - 1981
Y1 - 1981
N2 - We conducted a prospective, controlled, randomized trial of oral trimethoprim-sulfamethoxazole treatment in patients with acute leukemia receiving consolidation chemotherapy. We followed 14 treatment patients during 33 episodes and 15 control patients during 34 episodes of granulocytopenia (less than 1000 granulocytes/mm 3). We found no significant difference in the incidence of febrile episodes (13 in treatment group versus 14 in control group), hospitilizations to treat fever or infection (10 versus 12),number of documented infections (8 versus 10), number of septicemias (one versus two), or mean duration of hospital stay to treat fever or infection (8.9 versus 9.2 days) in the two groups. There was little colonization with organisms resistant to trimethoprim-sulfamethoxazole, including Candida, in either group. Prophylactic trimethoprim-sulfamethoxazole did not significantly reduce the incidence of fever, hospitalization, or infection in granulocytopenic patients during consolidation chemotherapy.
AB - We conducted a prospective, controlled, randomized trial of oral trimethoprim-sulfamethoxazole treatment in patients with acute leukemia receiving consolidation chemotherapy. We followed 14 treatment patients during 33 episodes and 15 control patients during 34 episodes of granulocytopenia (less than 1000 granulocytes/mm 3). We found no significant difference in the incidence of febrile episodes (13 in treatment group versus 14 in control group), hospitilizations to treat fever or infection (10 versus 12),number of documented infections (8 versus 10), number of septicemias (one versus two), or mean duration of hospital stay to treat fever or infection (8.9 versus 9.2 days) in the two groups. There was little colonization with organisms resistant to trimethoprim-sulfamethoxazole, including Candida, in either group. Prophylactic trimethoprim-sulfamethoxazole did not significantly reduce the incidence of fever, hospitalization, or infection in granulocytopenic patients during consolidation chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0019446625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019446625&partnerID=8YFLogxK
M3 - Article
C2 - 7025721
AN - SCOPUS:0019446625
VL - 95
SP - 436
EP - 438
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
SN - 0003-4819
IS - 4
ER -